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The idea of using cytotoxic drugs, toxins, or radioisotopes coupled to antibod- 
ies to destroy hidden tumor cells has been revitalized by the development of the 
monoclonal antibody (MAb) 1 technology (1). Selected MAb directed against 
tumor antigens, with their specificity for single antigenic determinants, appear 
to be the ideal carriers for antitumor agents. However, a prerequisite for all 
these forms of passive immunotherapy is that the antibodies are capable to reach 
the target umor cells in vivo. 
We have previously reported encouraging results of tumor localization by 
immunoscintigraphy in patients with colorectal carcinomas (2, 3) using one MAb 
(MAb 23) directed against carcinoembryonic antigen (CEA) (4, 5). However, the 
amount of radiolabeled antibody localizing specifically within the tumor mass 
was still relatively low as compared with the amounts of radioactivity remaining 
in the blood pool, reticuloendothelium, and various normal organs (2, 3). To 
improve these results we recently selected a series of MAb with higher affinities 
for CEA than the previously used MAb (6) and prepared F(ab')2 and Fab 
fragments. The fragments of high affinity MAb should give higher tumor uptakes 
with less accumulation i the reticuloendothelium and at the same time a more 
rapid clearance from the circulation. 
For ethical reasons and because tumors are very heterogenous in terms of size, 
anatomical sites, histology, vascularization, etc., it appears inappropriate oscreen 
the different MAb and their fragments for best tumor localization in patients. 
The model of nude mice bearing human colon carcinoma xenografts that we 
originally used for testing polyclonal anti-CEA antibodies in 1074 (7) offers the 
advantage of a relatively constant umor antigen expression and accessibility. 
Other groups have used similar experimental models of xenografted human 
* To whom correspondence should be addressed at the Institute of Biochemistry, University of 
Lausanne, 1066 Epalinges, Switzerland. 
~Abbreviations used in this paper: CEA, carcinoembryonic antigen; CNBr, cyanogen bromide; 
NCA, nonspecific cross-reacting antigen; MAb, monoclonal ntibody; PBS, phosphate-buffered saline; 
SDS, sodium dodecyl sulfate. 
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tumors to test the tumor-localizing capacity of polyclonal and monoclonal anti- 
bodies directed against various tumor markers (8-15), but no systematic 
comparison of different MAb and their fragments against he same marker have 
been reported. Despite the limitations of any experimental model of xenografted 
human tumors, namely the absence of normal human tissue as counterpart of 
the tumor transplant, we feel that these in vivo experiments are necessary for 
the final selection of MAb and fragments before human application. 
The purpose of this report is to compare the tumor localization capacity in 
vivo of four anti-CEA MAb with their F(ab')2 and Fab fragments in nude mice 
bearing human colon carcinoma grafts. The results showed a dramatic increase 
of specific tumor uptakes of radiolabeled F(ab')~ and Fab fragments as compared 
with intact antibodies and a marked improvement of tumor detection by external 
scanning in this experimental model. 
Materials and  Methods  
Production and Screening of Hybridomas. The derivation of 26 new hybridomas that 
secrete anti-CEA antibodies and their in vitro selection is described in detail elsewhere 
(6). Briefly, a BALB/c mouse was injected intraperitonally with 15 ~g of purified colon 
carcinoma CEA (16) in complete Freund's adjuvant. After 3 too, the mouse was reinjected 
with 15, 100, and 150 #g of purified CEA in saline at daily intervals (17). Spleen cells 
collected 6 d after the first boost were used for fusion with the myeloma cell line NSI/ 
lag4.1 (18). 
Hybridoma supernatants were screened for antibody production by a binding assay to 
radiolabeled CEA, using ammonium sulfate precipitation. Supernatants were also screened 
for strong inhibition of this binding by unlabeled CEA and for weak inhibition of this 
binding by a normal glycoprotein present in granulocytes and known to cross-react with 
CEA, called normal glycoprotein (NGP) (19) or nonspecific cross-reacting antigen (NCA) 
(20). Cross-reaction of hybridoma supernatant with granulocyte glycoprotein(s) (21) was 
also tested by immunoperoxidase staining of frozen sections of primary human colon 
carcinoma using the avidin-biotin system. After this in vitro screening, three new MAb, 
designated 35, 202, and 192, were selected for in vivo testing in parallel with MAb 23, 
which had already been used for tumor detection by immunoscintigraphy in patients (2, 
3). 
Pur~cation and Testing of Selected MAb. The selected hybrids were cloned by limiting 
7 dilution. Hybridoma scites were produced by injecting 10 hybrid cells intraperitoneally 
into Pristane (Aldrich, Beerse, Belgium)-primed BALB/c mice. MAb were purified from 
ascites by ammonium sulfate precipitation (45% saturation at 4°C) and DE 52 cellulose 
(Whatman, Balston, England) ion exchange chromatography. The MAb were eluted with 
a gradient of phosphate buffer, 0.01 to 0.15 M, pH 8 (22). A control IgG1 was purified 
by the same procedure, from ascites obtained with myeloma cell line P3×63Ag8 (1). 
The affinities of the four purified MAb for l~I-labeled CEA were determined both in 
0.02 M Tris-HC! buffer, pH 7.4, and in 0.15 M phosphate-buffered saline (PBS) using 
Scatchard Plot and Lineweaver Burke analysis. The affinities in low molarity Tris buffer 
of these four MAb were all in the range of 1.6-6.2 x 101° M-. The affinities in PBS were 
5.8 X 108, 1.1 X 10 9, 6 X 109, and 1.8 x 101° M- for MAb 23, 202, 35, and 192, 
respectively. By a radioimmunoassay (5) using immobilized CEA and goat antisera gainst 
mouse immunoglobulin sotypes (Meloy, Springfield, VA), it was shown that the four 
selected MAb were of IgGl subclass. 
Reciprocal binding inhibition tests on insolubilized CEA showed that MAb 23 and 202 
were reacting with the same or closely related epitopes on CEA, and MAb 35 and 192 
were reacting with different epitope.s The four purified MAb were also. tested for binding 
to purified soluble ~I-labeled NCA (20) (Commissariat Energie Atomlque, Gif sur Yvette, 
France) using ammonium sulfate precipitation, and for binding to the surface of freshly 
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~repared normal human granulocytes by an indirect binding radioimmunoassay using 
5I-labeled rabbit antibodies against mouse F(ab')2 (23). 
Preparation of F(ab')2 and Fab Fragments. F(ab')2 fragments of the four selected purified 
MAb and control IgG were obtained by incubation for 22 h at 370C with 5% (wt/wt) 
pepsine, (Worthington, Freehold N J) in acetate buffer, pH 4 (24), followed by filtration 
on Sephadex G-150 (Pharmacia, Uppsala, Sweden). Fab fragments of Mab 202 and 35 
and of control IgG were obtained by incubation for 6 h at 37°C with 2 or 3% (wt/wt) 
papain (Sigma Chemical Co., St. Louis, MO) in a 0.075 M phosphate buffer, pH 7, 
containing 0.075 M NaCI, 0.01 M L-cysteine hydrochloride, and 0.002 M EDTA (25). 
Fab fragments were separated from partially digested IgG by filtration on Sephadex G- 
150 and from Fc fragments by a DE-52 ion exchange chromatography column equilibrated 
in 0.01 M phosphate buffer, pH 8. The Fab fragments were eluted with the void volume, 
whereas the Fc fragments were retained. Purified intact MAb, and F(ab')2 and Fab 
fragments were analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide g l (8.5%) 
electrophoresis. They gave single bands with the expected molecular weights of about 
150,000, 105,000, and 50,000, respectively (Fig. 1). 
The affinities of two Fab fragments were measured after labeling with 1251 by the 
following method. First, increasing amounts of labeled Fab were incubated with a constant 
amount of unlabeled CEA. The CEA was then precipitated after incubation with a second, 
noncompetitive, intact Mab by addition of ammonium sulfate. The affinities in 0.02 M 
Tris buffer were 6.7 × 109 and 9.3 x 109, and in PBS, 4.1 x 109 and 1.1 x 10 s M-, for 
Fab of Mab 192 and 202, respectively. 
Iodine Labeling of Intact lgG and of Their Fragments. 20 #g of purified MAb or of their 
fragments were labeled with 1 mCi of ~31I using the Iodobeads method (Pierce Chemicals, 
Rockford, IL). Control IgG or its fragments were labeled under the same conditions with 
~5I. Free iodine was removed from the labeled proteins by dialysis or by Sephadex G-25 
chromatography. The specific radioactivity ranged from 20 to 40 ~Ci/~g of MAb for 
both isotopes. Labeled antibodies or their fragments were tested for binding activity by 
overnight incubation in 0.15 M PBS at 25 °C with 10 #g CEA bound to cyanogen bromide 
(CNBr)-activated Sepharose 4B (Pharmacia,). 
Injection of Nude Mice Bearing Grafts ofHuman Colon Carcinoma. The human colon 
carcinoma (Co-112) (7) maintained by serial transplantations into BALB/c nude mice 
produces CEA as demonstrated using immunoperoxidase (26). Transplanted tumors 
contain 50-100 #g CEA/g whereas era from mice bearing tumors of ~ 1 g contain 5- 
20 ng of CEA per ml of serum as determined by an enzyme immunoassay using anti-CEA 
Mab (27). Mice having tumors of 0.1-1.5 g (2-4 wk after transplantation) were chosen 
131-1 t for localization experiments. 200 #Ci of I-labeled Mab or F(ab )2 fragments and 300 
#Ci of labeled Fab fragments, representing 5-10 #g of protein, were injected intravenously 
together with 80 #Ci of ~25I-iabeled control IgG or its fragment, representing 2-4 #g of 
protein. The thyroids of the mice were blocked by addition of iodine (Lugol) solution in 
FIGURE 1. SDS-polyacrylamide gel (8.5%) electrophoresis of purif ed MAb 35 and 202 and 
their fragments. (A) intact 35, (B) F(ab')2 35, (C) Fab 35, (D) Fab 202, (E) F(ab')2 202, (F) 
intact 202. 
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the drinking water. 
Scanning and Dissection of Injected Animals. Whole-body scannings of mice anesthesized 
with Tribromoethanol (Merck, Mfinchen, Federal Republic of Germany [FRG]) were 
obtained by using a thyroid scanning unit (Picker Magnascanner 500) with a 131i collimator. 
After preliminary scanning studies performed at different times, we selected ay 3 after 
injection for intact MAb and day 2 for both types of fragments as the best times for 
systematic comparison of scannings. Similarly, days 4-5 for intact MAb, day 3 for F(ab')2, 
and day 2-3 for Fab were chosen for dissection of the animals and direct measurement 
of the radioactivity in the different organs. The mice were killed by ether anesthesia and 
0.5 ml of blood was taken from the vena cava. The tumor as well as all different organs 
including head and carcass were dissected, weighed, and counted for both iodine isotopes 
in a dual channel gamma counter. After differential radioactivity analysis, antibody and 
normal IgG concentrations were expressed in percentages of the total radioactivity 
recovered. Antibody and normal IgG (NIgG) uptakes into tumor were calculated by 
dividing the radioactivity concentration in the tumor by the corresponding concentration 
in individual normal organs or in the whole mouse (without he tumor). Finally, the 
specificity index of tumor localization was calculated by dividing the antibody uptake into 
the tumor by the normal IgG uptake according to the following formula: (MAb in tumor/ 
MAb in normal tissue)/(NIgG in tumor/NIgG in normal tissue). 
Autoradiography. The histological distribution of injected, radiolabeled MAb in tumors 
was analyzed by autoradiography. Mice bearing the tumor Co-112 (7) were injected 
intravenously with *~SI-labeled MAb or fragments, or with control IgG (160 ~Ci for intact 
MAb or F(ab')~ fragments and 240 t~Ci for Fab fragments corresponding to 5-10 #g of 
proteins). The mice were sacrificed the 4th d after injection of intact MAb and the 2nd d 
after injection of fragments. Half of the resected tumors were fixed in 2.5% glutaraldehyde 
and embedded in methacrylate, he other half were frozen in isopentane cooled by liquid 
nitrogen. Sections of 2 t~m for methacrylate-embedded tumors and of 8 ~m for frozen 
tumors were dipped in Ilford Nuclear Emulsion type L 4 (Ilford, Essex, UK) and developed 
2-4 mo later. Tissue sections were stained with nuclear fast red (Merck, Darmstadt, FRG). 
The CEA present in the same tumor was assessed by immunoperoxidase staining of the 
frozen section using MAb anti-CEA and the avidin-biotin system (26). These sections were 
counterstained with Gill's hematoxylin (Polysciences, Warrington, PA). 
Results 
In Vitro Selection and Testing of Intact MAb and Fragments. Four anti-CEA MAb 
were selected for the present study on the basis of the following criteria: MAb 
35 showed the highest specificity for CEA with no cross-reaction with NCA and 
no binding to human granulocytes. MAb 192 was selected because of its high 
affinity for CEA in physiologic molarity buffer (1.8 x 101° M-). However, its 
cross-reaction with NCA and human granulocytes would limit its use in human 
immunoscintigraphy. MAb 202 was taken because it appears to recognize the 
same epitope on CEA as the previously used MAb 23 but had a higher affinity 
in physiologic molarity buffer. MAb 23 had been used for immunoscintigraphy 
in patients with encouraging results and therefore served here as reference. MAb 
202 and 23 did not bind to purified radiolabeled NCA, but both bound to the 
surface of granulocytes. 
The percentages of binding of the radiolabeled, intact MAb, and their F(ab')2 
and Fab fragments to CEA immobilized on CNBr-activated Sepharose, obtained 
in PBS are shown in Table I. They ranged between 50 and 78% for MAb and 
their fragments. Labeled control normal IgG and fragments gave 2.3-6.4% of 
binding to the same CEA-Sepharose. 
Tumor Localization of MAb Studied by Paired Labeling Experiments. Groups of 4-  
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TABLE I 
Percentages ofBinding of Radiolabeled MAb and Fragments to CEA 
Coupled to Sepha rose 
MAb Control IgG MAb form 
35 192 202 23 (P3×63Ag8) 
Intact 70 (2.1)* 67 (3.6) 78 (4.0) 58 (1.9) 6.4 
F(ab')2 77 (2.6) 67 (2.9) 76 (3.2) 54 (3.2) 3.5 
Fab 65 (5.5) ND 50 (4.1) ND 2.3 
* Percentage of antibody radioactivity bound to CEA-Sepharose is fol- 
lowed by the individual background value (in parenthesis) obtained for 
each MAb or fragment with Sepharose containing bovine serum albu- 
min. ND, not done. 
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FIGURE 2. Distribution of MAb 35 or its fragments and control IgG or fragments injected 
simultaneously into nude mice bearing grafts of a human carcinoma. The concentration of 
antibody (shaded bars) and control IgG (open bars) per gram of tissue is expressed in 
percentages of total specific radioactivity recovered atvarious times after injection as indicated 
in the text. The vertical lines represent the standard eviations calculated from groups of four 
to seven animals per MAb or fragment. T, tumor; S, spleen; Li, liver; K, kidneys; GI, 
gastrointestinal tract; H, heart; Lu, lungs; SG, salivary glands; C, carcass and head; B, blood. 
7 nude mice bearing grafts of  the human colon carcinoma Co-112 were injected 
simultaneously with ~3~I-labeled MAb or their fragments and with their normal 
IgG counterpart  labeled with l~SI, and were dissected 2-5  d later. The  results of  
antibody and normal IgG concentrations per gram of  tumors and normal organs 
(expressed in percentage of  total radioactivity recovered for each isotope) are 
shown in Figs. 2-5.  The  tumor  uptakes for antibody and normal IgG calculated 
by comparison with individual normal organs and with the whole mouse are 
shown in Fig. 6. The  specificity indices of  tumor  localization compared with the 
whole animal are shown in Table II. 
For intact MAb the tumor  antibody uptakes as compared with the whole mouse 
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ranged between 7 and 15 and the specificity indices between 3.4 and 6.8. The 
lowest values were obtained with MAb 35 and the highest with MAb 202. 
Compared with intact MAb, the F(ab')2 fragments gave markedly increased 
tumor uptakes with values ranging between 12 and 24, as well as higher specificity 
indices, ranging between 5.3 and 8.2. The highest results for F(ab')~ fragments 
were observed with MAb 35 followed by MAb 202. 
Fab fragments from the two most promising MAb (clone 35 and 202) were 
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prepared and tested. They both gave very high tumor uptakes of 34 and 82, and 
specificity indices of 12 and 19, for Fab 202 and 35, respectively. It is interesting 
that the Fab fragment of MAb 35 gave the best results, because MAb 35 is also 
the most specific anti-CEA MAb, since it does not cross-react with granulocyte 
glycoprotein(s). 
The specificity indices calculated for different organs (data not shown) were 
rather constant for one type of MAb or fragment and consequently very close 
to the mean values hown in Table II. The stability of these specificity indices is 
also reflected by the fact that tumor uptakes of antibodies plotted against hose 
of control IgG fall on a straight line, whose slope is the expression of the 
specificity of tumor localization (Fig. 6). Tumor uptakes can show large variations 
in relation to the degree of vascularization of different organs but specificity 
indices are more constant and thus represent more meaningful values. 
The marked increase of tumor uptakes and specificity indices observed with 
MAb fragments i in part due to their more rapid elimination, as shown by the 
decrease of concentration of recovered radioactivity from the whole animal 
(Table III.) The absolute concentration of fragments in tumors was also de- 
creased (as compared to intact MAb) but to a lesser degree than their concentra- 
tion in normal tissues (Table III). 
External Scanning Studies. Intact MAb gave clear tumor detection by scanning 
only 3 d after injection, for relatively large tumors of 0.5-1 g as shown in Fig. 
7A. The failure to detect tumors of smaller size or at earlier times was due 
mostly to the abundance of labeled intact MAb in the blood and thus in the well- 
vascularized organs, as determined in a few animals sacrificed and dissected at 
day 2 and 3 (data not shown), and by the results obtained at day 4-5 (Fig. 2-5). 
F(ab')~ fragments gave earlier positive tumor detection at day 2 (Fig. 7B) but 
these fragments did not give very contrasted scannings for tumors smaller than 
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0.5g. 
The best scanning results were obtained with Fab fragments which allowed 
the clear detection of tumors weighing only 0.1-0.3 g 2 d after injection (Fig. 
7, C and D). It should be noted that all scanning pictures hown represent raw 
data without any computerized background subtraction. 
Autoradiographs of Tumor Sections. Autoradiographs demonstrate hat injected 
labeled MAb and fragments localized in tumor nodules and not in the stromai 
connective tissue of mouse origin, as shown for intact MAb (Fig. 8A). However, 
BUCHEGGER ET AL. 
TABLE II 
Spec~city Indices of Tumor Localization Obtained with Intact MAb and 
Fragments 
421 
MAb 
MAb form 
35 192 202 23 
Intact 3.4 ± 0.7* 3.6 ± 0.3 6.8 ± 2.7 5.0 ± 0.7 
F(ab')2 8.2 ± 5.7 7.5 ± 5.0 7.9 ± 3.3 5.3 ± 1.3 
Fab 19.0 ± 5.5 ND 11.9 ± 4.3 ND 
* The specificity indices ± the standard eviation were calculated by 
comparison with the normal tissue of the whole mouse according to the 
formula given in Materials and Methods. ND, not done. 
TABLE III 
Absolute Concentration f Antibody Radioactivity Recovered in Tumors and in Whole Mice 
MAb MAb form Tumor Mouse normal tissues 
MAb 35 
MAb 202 
Intact (day 4-5)* 18.2 _ 6.3' (9.1) e 2.61_+0.46'(1.31) 0 
F(ab')2 (day 3) 4.9 _+ 2.5 (2.5) 0.20 - 0.03 (0.10) 
Fab (day 2-3) 7.5 _ 1.2 (2.5) 0.09 + 0.02 (0.03) 
Intact (day 4-5) 9.1 ± 2.5 (4.5) 0.58 ± 0.20 (0.29) 
F(ab')2 (day 3) 3.4 ± 1.0 (1.7) 0.15 ± 0.06 (0.08) 
Fab (day 2-3) 2.9 ± 1.3 (1.0) 0.09 ± 0.02 (0.03) 
* Days of dissection and counting. 
* Absolute concentration of antibody radioactivity recovered in ~Ci/g of tissues _ standard 
deviation (corrected for physical half-life of isq). 
a Concentration of antibody radioactivity recovered per gram of tissue xpressed in percent 
of injected ose (corrected for physical half-life of zslI). 
the labeled intact MAb were not distributed homogeneously in the entire tumor  
tissue. There  were areas of  intense concentration of  radioactivity in nonnecrotic 
tumor  tissue, whereas other areas morphologically very similar contained much 
less radioactivity. The  high concentration of  radioactivity at the periphery of 
tumor  nodules suggests that the vascularization was an important factor for this 
antibody distribution. In contrast, necrotic areas of the tumor showed diffuse 
and very low concentrations of radioactivity. 
Labeled F(ab')~ and Fab fragments appeared to penetrate deeper into the 
tumor  nodules and to concentrate in the pseudolumen of  the malignant glands 
(Fig. 8, B and C) that contained the highest concentration of  CEA, as shown by 
in vitro immunoperoxidase taining on frozen sections from the same tumor 
(Fig. 8D). Mice injected with labeled control normal IgG or f ragment showed 
very low diffuse radioactivity in the tumor  (data not shown). 
Discussion 
We describe herein the first thorough comparative study of  tumor localization 
in vivo of  intact MAb and their F(ab')~ and Fab fragments directed against a 
tumor-associated antigen. Radiolabeled fragments, in particular Fab, gave much 
higher tumor  uptakes and better tumor  detection by external scanning than did 
intact MAb in the model of  nude mice grafted with a human colon carcinoma. 
This experimental  model was chosen because human colon carcinomas grafted 
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FIGURE 7. Whole-body scannings of nude mice bearing grafts of a human colon carcinoma 
obtained after intravenous injection of I 'I-labeled MAb or fragments. (A) Mouse injected with 
intact MAb 202; tumor weighing 1 g, scan obtained at day 3 after injection. (B) MAb 202 
F(ab')2 fragment, umor of 0.7 g~ scan at day 2. (C) MAb 202 Fab fragment, tumor of 0.3 g, 
scan at day 2. (D) MAb 35 Fab fragment, tumor of 0.1 g, scan at day 2. Scans shown atthe 
right of the corresponding mice represent raw data without any background subtraction. 
in nude mice retain the same histological morphology as the primary human 
tumor (28), and synthetize and release CEA (7), as observed in patients. The  
specificity of  the results was assessed by using the paired labeling method 
described by Pressman et al. (29) in which a control mouse IgG or its fragments 
labeled with 1~5I is injected simultaneously with the 13~I-labeled MAb. This 
internal control allows one to correct for any nonspecific accumulation of  labeled 
proteins in tumor tissues and the calculated specificity indices represent the most 
relevant evaluation of  the MAb's capacity to bind to antigens present in the 
tumor. 
It was of  particular interest o evaluate antibody fragments, since our prelim- 
inary clinical results using F(ab')2 fragments from our first anti-CEA MAb (2) 
and from a MAb directed against another colon carcinoma ntigen (30) suggested 
that these fragments gave less nonspecific accumulation of  radioactivity in the 
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reticuloendothelium than intact MAb. However, clinical results are often difficult 
to interpret since they are derived from the evaluation of photoscanning pictures, 
and direct measurement of radioactivity can be obtained only from surgically 
resected malignant and normal tissues. Thus, the present experimental results 
represent a much stronger argument in favor of using fragments of MAb for the 
detection of tumor in patients. In particular, the fragments of MAb 35, which 
gave the highest umor uptakes and the least cross-reaction with human granu- 
locytes, appear to be the best candidate for localization of colorectai carcinoma 
by immunoscintigraphy in patients. 
Our autoradiographic results confirmed the specificity of tumor localization 
of anti-CEA MAb and fragments at the histological level and differ from those 
of Lewis et al. (31) who reported that radiolabeled intact goat anti-CEA antibodies 
localized in the stromal connective tissue of mouse origin present within the 
grafted human tumor. Despite their specificity, however, our results provide a 
warning for those who are already considering the use of radiolabeled anti-CEA 
antibodies for therapy (32), since the autoradiographs show that the labeled 
MAb localized in areas with high CEA concentration but not on all carcinoma 
cells. Therefore if radiotherapy with radiolabeled MAb is considered one should 
select isotopes capable of destroying tumor cells within a radius of 50-100 #m. 
High energy alpha- or beta-emitting isotopes with these properties can be coupled 
to antibodies by metal chelates uch as diethylenetriamine p ntaacetic acid (33, 
34). Using this chelate, we have recently coupled l lqndium to MAb 35 and 
shown that after injection into nude mice, it gave similar tumor uptakes as those 
obtained with a3q-labeled MAb. Thus, the MAb and the nude mouse model 
described here should provide a means to evaluate the possibility of destroying 
human solid tumors by radioimmunotherapy. 
Summary  
Four monoclonal antibodies against carcinoembryonic antigen (CEA) have 
been selected from 32 hybrids that produce antibodies against his antigen, by 
the criteria of high affinity for CEA and low cross-reactivity with granulocyte 
glycoprotein(s). The specificity of tumor localization in vivo of the four MAb, 
and their F(ab')2 and Fab fragments was compared in nude mice bearing grafts 
of a serially transplanted, CEA-producing, human colon carcinoma. The distri- 
bution of radiolabeled MAb and their fragments after intravenous injection was 
analyzed by direct measurement of radioactivity in tumor and normal organs, as 
well as by whole-body scanning and by autoradiography of tumor sections. Paired 
labeling experiments, in which l sa I-labeled antibody or fragments and l~SI-labeled 
control IgG are injected simultaneously, were undertaken to determine the 
relative tumor uptakes of each labeled protein. The tumor antibody uptake 
divided by that of control IgG defines the specificity index of localization. Tumor 
antibody uptakes (as compared with the whole mouse), ranging between 7 and 
15, and specificity indices ranging between 3.4 and 6.8, were obtained with the 
four intact MAb at day 4-5 after injection. With F(ab')2 fragments of the four 
MAb, at day 3, the tumor antibody uptakes ranged between 12 and 24 and the 
specificity indices between 5.3 and 8.2. With the Fab fragments prepared from 
the two most promising MAb, the antibody uptakes reached values of 34 and 82 
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at day 2-3 and the specificity indices were as high as 12 and 19. The scanning 
results paralleled those obtained by direct measurement of radioactivity. With 
intact MAb, tumor grafts of 0.5-1 g gave very contrasted positive scans 3 d after 
injection. Using MAb fragments, tumors of smaller size were detectable earlier. 
The best results were obtained with Fab fragments of MAb 35, which gave clear 
detections of tumors weighing only 0.1 g as early as 48 h after injection. 
Autoradiographs of tumor sections from mice injected with 125I-labeled MAb 
demonstrated that the radioactivity was localized in the tumor tissues and not in 
the stromal connective tissue of mouse origin. The highest radioactivity concen- 
tration was localized in areas known to contain CEA such as the pseudolumen of 
glands and the apical side of carcinoma cells. The penetration of radioactivity in 
the central part of tumor nodules and the pseudolumen appeared to be increased 
with the use of MAb fragments. 
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